NEW YORK (GenomeWeb) – Emedgene, a startup developer of automated genomic interpretation software, said today that it has raised $6 million in a Series A funding round led by Olive Tree Ventures.
The Palo Alto, California-based company with Israeli roots said that it will use the money to expand its US sales operations. CEO Einat Metzer has moved to Silicon Valley, though R&D operations remain in Tel Aviv, a company spokeswoman said.
Emedgene has built and trained an artificial intelligence engine to interpret genetic tests, taking the workload off of geneticists. The platform is capable of finding causative variants and supporting evidence for genome sequences, exome sequences, and gene panels to help clinicians diagnose rare diseases, screen healthy populations, and practice pharmacogenomics, the company said.
Customers include Israel's recently launched National Genomic and Personalized Medicine Initiative, which is attempting to sequence at least 100,000 genomes by 2023.
"Genetic medicine will inevitably become the medical standard of care, if we can remove the hurdles to wider adoption. Emedgene does just that, with AI that can surface scientific knowledge in clinical settings, so that every patient has access to the best possible care," Metzer said in a statement.